RhumbLine Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
RhumbLine Advisers's LKFT Position: Q3 2026 in Review
RhumbLine Advisers increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 0.08% in Q3 2026, buying an estimated $172 and bringing the position to 7,303 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #3237.
RhumbLine Advisers first reported a position in LKFT in Q2 2023 and has held it in 14 quarters since. The position peaked at $228K in Q4 2025. 95 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.
- RhumbLine Advisers held 7,303 shares of Lakefront Biotherapeutics American Depositary Shares worth $217K as of Q3 2026.
- RhumbLine Advisers bought 6 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2026, an estimated $172.
- Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3237 holding.
- RhumbLine Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2023 and has held it in 14 quarters since.
- RhumbLine Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $228K in Q4 2025.
- 95 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.